Neostigmine

Generic Name: Neostigmine

Brand Names: Bloxiverz, Prevduo, Prostigmin

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₉N_₂O_₂

CAS Number: 59-99-4

Unique Ingredient Identifier: 3982TWQ96G

Background: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.

Indication: Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.

Associated Conditions: Curarization therapy, Myasthenia Gravis, Neuromuscular Blockade, Postoperative Urinary Retention (POUR), Acute Colonic Pseudo-Obstruction, Post-operative intestinal atony

Associated Therapies: -

Clinical Trials

Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea

Phase 4

Completed

Conditions: Obstructive Sleep Apnea

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2014-06-10

Last Posted Date: 2014-12-09

Lead Sponsor: Diskapi Teaching and Research Hospital

Target Recruit Count: 74

Registration Number: NCT02160223

Locations: 🇹🇷
Diskapi Yildirim Beyazit Teaching and Research Hospital, Ankara, Turkey

The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy

Not Applicable

Completed

Conditions: Robot-Assisted Laparoscopic Radical Prostatectomy

Interventions: Procedure: deep neuromuscular blockade
Procedure: moderate neuromuscular blockade
Drug: Rocuronium
Drug: Atracurium
Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2014-04-09

Last Posted Date: 2015-06-24

Lead Sponsor: Yonsei University

Target Recruit Count: 67

Registration Number: NCT02109133

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of

Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?

Not Applicable

Completed

Conditions: Respiratory Complication
Morbid Obesity

Interventions: Device: Accelomyography
Drug: Neostigmine
Device: Qualitative Monitor

First Posted Date: 2014-01-16

Last Posted Date: 2016-02-05

Lead Sponsor: Coastal Anesthesiology Consultants

Target Recruit Count: 330

Registration Number: NCT02037516

Locations: 🇺🇸
Flagler Hospital, St. Augustine, Florida, United States

A Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Sugammadex Versus Neostigmine in Improving Surgical Condition in Subjects Undergoing Laryngeal Microsurgery

Not Applicable

Completed

Conditions: General Anesthesia

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2013-11-08

Last Posted Date: 2015-04-23

Lead Sponsor: Yonsei University

Target Recruit Count: 72

Registration Number: NCT01980069

Locations: 🇰🇷
Severance Hospital, Seoul, Seodaemun-gu, Korea, Republic of

Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex

Phase 3

Completed

Conditions: Diaphragmatic Dysfunction
Muscle Weakness
Muscle Fatigue

Interventions: Drug: sugammadex 4mg/kg
Drug: sugammadex 2mg/kg
Drug: placebo
Drug: neostigmine
Drug: Repeated rocuronium dose
Drug: Continuous rocuronium infusion
Drug: Single rocuronium dose

First Posted Date: 2013-10-14

Last Posted Date: 2018-10-24

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 75

Registration Number: NCT01962298

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Antwerpen, Belgium

Reversal of Neuromuscular Blockade in Thoracic Surgical Patients

Completed

Conditions: Residual Neuromuscular Blockade

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2013-04-23

Last Posted Date: 2020-02-13

Lead Sponsor: NorthShore University HealthSystem

Target Recruit Count: 200

Registration Number: NCT01837498

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States

Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial

Phase 3

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Sugammadex
Drug: Neostigmine

First Posted Date: 2013-03-13

Last Posted Date: 2014-03-06

Lead Sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia

Target Recruit Count: 100

Registration Number: NCT01809886

Locations: 🇪🇸
Mª Dolores Cárceles Barón, El Palmar, Murcia, Spain

Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients

Phase 2

Conditions: Morbid Obesity
Neuromuscular Blockade

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2012-06-27

Last Posted Date: 2012-06-27

Lead Sponsor: University of Patras

Target Recruit Count: 120

Registration Number: NCT01629394

Locations: 🇬🇷
University of Patras, Department of Anesthesiology and Critical Care Medicine, Patras, Achaia, Greece

Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)

Phase 3

Completed

Conditions: Surgical Procedures, Elective

Interventions: Drug: Sugammadex
Drug: Neostigmine
Drug: Glycopyrrolate

First Posted Date: 2011-11-24

Last Posted Date: 2017-06-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 154

Registration Number: NCT01479764

Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block

Phase 4

Completed

Conditions: Airway Reflexes, Protective
Recovery After Neuromuscular Block
Anesthetic Recovery

Interventions: Drug: Sevoflurane
Drug: Desflurane
Drug: Rocuronium
Drug: Neostigmine
Drug: Glycopyrrolate

First Posted Date: 2010-09-10

Last Posted Date: 2014-05-16

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 107

Registration Number: NCT01199237

Locations: 🇺🇸
UCSF Moffitt-Long Hospital, San Francisco, California, United States
🇺🇸
UCSF Helen Diller Cancer Center, San Francisco, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy